Emeline B.
- Country
- Belgium
- Department
- Paediatrics
Research Overview
- Evaluation of Efficacy and Safety of Oral Ozanimod in Pediatric Patients with Moderately to Severely Active Ulcerative Colitis Unresponsive to Conventional Therapy
- Evaluation of Ozanimod Efficacy and Safety in Pediatric Patients with Moderate to Severe Crohn's Disease Unresponsive to Conventional Therapy
- Evaluation of Anti-TNF Therapy De-escalation Using Adalimumab and Infliximab in Adolescents and Young Adults with Inflammatory Bowel Disease
Data & Insights
Has run more than one trial at 14 of 54 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating inflammatory bowel disease (IBD), with particular emphasis on both Crohn's disease and ulcerative colitis in pediatric and adult populations.
- Pediatric IBD Treatment
- Therapeutic Drug Monitoring
- Treatment-Resistant IBD
A key focus includes managing moderate to severe cases that have shown inadequate response to conventional therapies.
Pediatric Gastroenterology
The investigator demonstrates particular expertise in pediatric gastroenterological conditions, focusing on innovative therapeutic approaches for young patients with inflammatory bowel conditions.
- Pediatric Crohn's Disease
- Pediatric Ulcerative Colitis
- Novel Therapeutic Applications
Their work encompasses evaluation of new treatment modalities specifically adapted for pediatric patients.
Treatment Optimization
The investigator focuses on therapeutic optimization strategies for IBD treatment, including the development of personalized dosing approaches.
- Biomarker-Guided Therapy
- Treatment Interval Assessment
- Remission Maintenance Strategies
Expertise includes developing strategies for maintaining disease remission through careful therapeutic monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.